Extended Data Fig. 10: Knockdown of IGF2BP1/3 inhibits cell proliferation and metastasis in HCC.
(a) The RNA levels of IGF2BP1/3 in Hep3B cells with lnc-CTHCC knockdown. (b) Western blot assays of IGF2BP1/3 in different cells with lnc-CTHCC knockdown or overexpression. The results are representative of three independent experiments. (c,d) The knockdown efficiencies of IGF2BP1/3 at the RNA and protein levels in Hep3B cells. P values are as follows: P = 0.0006 (si-IGF2BP1-1); P = 0.0006 (si-IGF2BP1-2); P = 0.0002 (si-IGF2BP3-1); P = 0.0002 (si-IGF2BP3-2). For D, the results are representative of three independent experiments. (e,f) Knockdown of IGF2BP1/3 inhibited cell proliferation and metastasis in Hep3B cells. (e) P values are as follows: P = 0.0016 (si-IGF2BP1-1); P = 0.0027 (si-IGF2BP1-2); P < 0.0001 (si-IGF2BP3-1); P < 0.0001 (si-IGF2BP3-2). (f) Scale bars = 50 μm. P values are as follows: P = 0.0012 (migration-si-IGF2BP1-1); P = 0.0003 (migration-si-IGF2BP1-2); P = 0.0009 (invasionsi-IGF2BP1-1); P < 0.0001 (invasion-si-IGF2BP1-2); P = 0.0006 (migration-si-IGF2BP3-1); P = 0.0009 (migration-si-IGF2BP3-2); P = 0.0008 (invasion-si-IGF2BP3-1); P = 0.0009 (invasion-siIGF2BP3-2). (g) Schematic diagram showing the molecular mechanisms underlying lnc-CTHCC action in hepatocellular carcinoma. For A, C and E-F, data are from three biologically independent experiments and shown as mean ± SEM. Two-tailed paired t-test was performed. **P < 0.01; ***P < 0.001; ****P < 0.0001.
